Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555853 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01555853 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT01555853, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies are needed to treat patients with relapsed and refractory lymphomas. Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the anticancer drug concentration in the tumor while reducing toxic effects in normal tissue and may be an effective treatment for lymphoma.
Interventions
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555853
The ClinicalTrials.gov registry entry for NCT01555853 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abraxane is the first listed.
NCT01555853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555853 about?
NCT01555853 is a clinical study titled "Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma". This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies a...
What is the current status of trial NCT01555853?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01555853?
The interventions under investigation include: Abraxane (DRUG).
Who is sponsoring clinical trial NCT01555853?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.